Polymerase News and Research

RSS

PCR Biosystems introduces RiboShield RNase Inhibitor for use in RNA-sensitive applications

PCR Biosystems has today launched RiboShield RNase Inhibitor. Already an important component of several PCR Biosystems kits, this robust and reliable RNase inhibitor is, for the first time, available as a standalone product.

From PCR Biosystems Ltd. 10 Sep 2020

Convalescent plasma fails to improve outcome of COVID-19 in India

A new study based in India and published on the medRxiv preprint server explores the role of convalescent plasma (CP) in the treatment of moderate COVID-19 within the limitations on resources faced in a developing country.

9 Sep 2020

Brain inflammation seen in fatal COVID-19 cases

Now, a new study by researchers at the Barts Health NHS Trust and the University of Cambridge in the United Kingdom shows that some patients develop neurological complications tied to COVID-19.

9 Sep 2020

Pfizer, BioNTech COVID-19 vaccine candidate shows promise in preclinical study

Researchers in the United States and Germany have conducted a study demonstrating the preclinical efficacy of a new candidate vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the agent that causes coronavirus disease 2019 (COVID-19).

9 Sep 2020

Host gene editing main driving force of SARS-CoV-2 mutations

A new study published on the aRxiv preprint server in September 2020 shows that the host immune response, mediated by two RNA editors, causes the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to adapt and change strain characteristics.

9 Sep 2020

Pooled saliva testing increases COVID-19 testing capacity

Now, a new study by researchers at Yale School of Medicine and published on the preprint server medRxiv in September 2020 shows that pooled saliva samples can save resources and increase testing capacity, making a significant difference in the management of the pandemic.

7 Sep 2020

Using proteins to track SARS-CoV-2 infections through wastewater

A new study published on the preprint server medRxiv* in September 2020 describes the measurement of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) proteins in wastewater as a reliable way to track the virus in the community.

6 Sep 2020

Study shows SARS-CoV-2 cell receptor is a novel target of the gamma-secretase enzyme complex

Based on structural similarities with other targets of the gamma-secretase system, researchers from Columbia University Irving Medical Center in the United States show that the SARS-CoV-2 receptor for cell entry may be affected by its proteolytic activity. Their results are currently freely available in a bioRxiv preprint paper.

6 Sep 2020

Understanding SARS-CoV-2 evolution requires more focus on structural variants

Researchers in the United States and Canada warn that more attention needs to be paid to the role that structural variants and recombination in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have played in the evolutionary history of the virus.

3 Sep 2020

Chest X-rays found to be highly predictive of COVID-19

A team of LSU Health New Orleans radiologists investigated the usefulness of chest X-rays in COVID-19 and found they could aid in a rapid diagnosis of the disease, especially in areas with limited testing capacity or delayed test results.

3 Sep 2020

Antibody responses in recovered COVID-19 individuals from India

India has been hit hard by COVID-19, with at least 66,000 deaths and almost 4 million cases. The need to understand the infection, including the various antibody isotypes, and whether neutralizing antibodies and memory B cells are being produced, has driven much research into the way immunity is developing in Indian patients.

3 Sep 2020

Study shows SARS-CoV-2 jumps back and forth between animals and humans on mink farms

An in-depth investigation of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreaks on 16 mink farms by researchers from the Netherlands revealed that minks might serve as a reservoir for persistent infection in humans. The study is currently available on bioRxiv* preprint server.

2 Sep 2020

Durable IgG antibodies to SARS-CoV-2 from the Iceland experience

Now, a team of scientists at the Reykjavik-based deCODe Genetics, a subsidiary of the U.S. biotech company Amgen, and several universities and hospitals in Iceland, says that the antibodies developed to fight SARS-CoV-2 last for at least four months and do not fade quickly as previously thought.

2 Sep 2020

SARS-CoV-2-RNA viremia is a robust marker of critical illness in COVID-19

A new study by a large team of Spanish researchers and published on the preprint server medRxiv* in August 2020 reports that the presence of viral RNA in the blood is a useful marker of impending acute disease and can help triage COVID-19 disease patients who will require hospital care.

1 Sep 2020

Human antibody response to SARS-CoV-2

A new study published on the preprint server medRxiv* in August 2020 reports on the human antibody response in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which is key to developing vaccines and managing the pandemic, as well as designing and executing serologic testing and interpreting their results.

1 Sep 2020

T cell epitopes from recovered COVID-19 patients identified for vaccine

A new study by researchers at The Hong Kong University of Science and Technology and published on the preprint server bioRxiv in August 2020 collates the available database of SARS-CoV-2 T cell epitopes gathered from 8 studies of COVID-19 patients who recovered. This could serve as a launchpad to fill in knowledge gaps regarding the immunological aspects of this disease, and drive towards an effective T cell vaccine.

31 Aug 2020

New lipid derivatives of Remdesivir have higher anti-coronavirus activity

In a fascinating new preprint paper published on bioRxiv* in August 2020, the researchers report “the synthesis and antiviral evaluation of three novel lipophilic prodrugs of RVn-monophosphate that are substantially more active than Remdesivir in cells infected with SARS-CoV-2.” These could be of immense use in treating COVID-19 patients early and helping to end transmission.

30 Aug 2020

SARS-CoV-2 Neucleocapside (N) protein is heavily glycosylated

However, the nucleocapsid (N) protein is also extremely abundant and, therefore, a useful target for both vaccine and diagnostic test development. A new study published on the preprint server bioRxiv in August 2020 reveals the structure of this protein, a valuable step in using it for these purposes.

30 Aug 2020

Severe and fatal COVID-19 is rare in children

Now, a new study by researchers at the Universities of Edinburgh and Liverpool, Imperial College London, and the Royal Hospital for Children, Glasgow in the United Kingdom has shown that children and teenagers are less likely than adults to develop severe COVID-19 or die from the disease.

30 Aug 2020

FDA grants Abbott's COVID-19 rapid antigen test emergency-use authorization

Now, the U.S. Food and Drug Administration has granted emergency-use authorization to Abbott Laboratories for a $5 rapid-response COVID-19 antigen test, called BinaxNOW COVID-19 Ag Card, which is roughly the size of a credit card.

27 Aug 2020